

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

GENERAL DISCLOSURE PURSUANT TO RULE 13.18 OF THE LISTING RULES

This announcement is made pursuant to Rule 13.18 of the Listing Rules with respect to the Loan Agreement, which contains specific performance obligations imposed on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) with respect to a loan agreement dated 19 June 2009 (the “**Loan Agreement**”) entered into between Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) (as borrower) and Citic Ka Wah Bank Limited (“**Citic Ka Wah Bank**”) (as lender), which contains specific performance obligations imposed on the controlling shareholders of the Company.

The Loan Agreement is for a term loan facility of HK\$50,000,000, the final maturity date of which shall be the date falling 36 months after the date of the Loan Agreement, and the drawdown date shall be within 3 months from the date of the Loan Agreement.

The Loan Agreement provides that from the date of the Loan Agreement and, so long as the indebtedness under the Loan Agreement remain outstanding, the Company will procure that: (1) Prime United Industries Limited (“**Prime United**”) and China Pharmaceutical Company Limited (“**CPCL**”) shall in aggregate maintain not less than 50% beneficial ownership of the shareholding of the Company; and (2) Mr. Wu Qin and Mr. Qu Jiguang shall remain as directors of the Company.

Any breach of the above specific performance obligations would constitute a default under the Loan Agreement. Such default would allow Citic Ka Wah Bank to declare (i) the facility terminated and (ii) all the indebtedness under the Loan Agreement become due and payable.

As at the date of this announcement, Prime United and CPCL respectively own 31.29% and 28.19% of equity interest of the Company. Mr. Wu Qin holds 2.43% of beneficial interest of equity interest of Prime United; and holds jointly, with the executive Directors, namely Mr. Huang Chao and Mr. Xie Yunfeng, and Ms. Han Yamei, a member of the management of Xi'an Lijun Pharmaceutical Co., Ltd. (西安利君製藥有限責任公司) (“**Xi'an Lijun**”), an aggregate of 84.73% of equity interest of Prime United, on trust for 4,536 individuals, who are present and former employees or their respective estates of Xi'an Lijin and Rejoy Group Limited Liability Company (利君集團有限責任公司) (“**Rejoy Group**”). Mr. Wu Qin is also a director of Prime United. Xi'an Lijun is a company established in the PRC with limited liability and wholly-owned by the Company. Rejoy Group is a company established in the PRC with limited liability and 100% owned by Shaanxi Pharmaceutical Company (陝西省醫藥總公司), a state-owned enterprise under the direct supervision of the Shaanxi Provincial Government. Mr. Qu Jiguang holds 72.93% of beneficial interest of equity interest of CPCL and is a director of CPCL.

This announcement is made pursuant to Rule 13.18 of the Listing Rules. In accordance with the requirements thereunder, disclosure will be included in the interim and annual reports of the Company for so long as the above specific performance obligations continue to exist.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 19 June 2009

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xianjun, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu, Mr. Bao Leyuan as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.